Sequencing Of Agents And Combination Therapy In Castrate Resistant Prostate Cancer

Co-Host: Maxwell Meng, MD At the conclusion of these activities, participants will be able to: 1. Identify treatments for non-metastatic and metastatic CRPC and describe the proper order for their administration. 2. Manage nm and mCRPC with systemic agents by learning the proper candidates for treatment and be able to counsel patients on the pros and cons of therapy. 3. Review the newer generation antiandrogen agents and their use in nmCRPC and in mCRPC. CME Available: auau.auanet.org/node/26067 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma